ABCB1 rs12720067: Understanding Pharmacogenetic Research
The rs12720067 variant is a single-nucleotide polymorphism located within the ABCB1 gene, which encodes the P-glycoprotein efflux pump. Researchers investigate this variant for its potential influence on how the brain processes certain antidepressant medications, though clinical evidence remains inconsistent.
What each genotype means
Typical ABCB1 variant profile
This genotype represents one of the common variations in the ABCB1 gene, which encodes the P-glycoprotein efflux pump. While research has investigated whether this variant influences how antidepressants are transported across the blood-brain barrier, current evidence is limited and inconsistent. You should not use this information to make decisions about your medication; please discuss any concerns regarding your treatment response or dosing with your clinician or pharmacist.
This genotype is common, though exact frequencies vary by ancestral background.
Typical ABCB1 variant profile
This genotype represents one of the common variations in the ABCB1 gene, which encodes the P-glycoprotein efflux pump. While research has investigated whether this variant influences how antidepressants are transported across the blood-brain barrier, current evidence is limited and inconsistent. You should not use this information to make decisions about your medication; please discuss any concerns regarding your treatment response or dosing with your clinician or pharmacist.
This genotype is common, though exact frequencies vary by ancestral background.
Typical ABCB1 variant profile
This genotype represents one of the common variations in the ABCB1 gene, which encodes the P-glycoprotein efflux pump. While research has investigated whether this variant influences how antidepressants are transported across the blood-brain barrier, current evidence is limited and inconsistent. You should not use this information to make decisions about your medication; please discuss any concerns regarding your treatment response or dosing with your clinician or pharmacist.
This genotype is common, though exact frequencies vary by ancestral background.
What is rs12720067?
The rs12720067 variant is a specific genetic change, or single-nucleotide polymorphism (SNP), found within the ABCB1 gene. In genetics, a SNP represents a variation at a single position in the DNA sequence among individuals. This particular variant is located in a region of the genome that has been studied for its potential to influence how the body handles various substances. Because the ABCB1 gene is highly active in the blood-brain barrier, researchers are interested in whether variations like rs12720067 alter the expression or efficiency of the proteins produced by this gene. While the variant is well-documented in genomic databases, it is important to distinguish between the presence of a genetic marker and its functional impact on human health. Scientific studies often look at such variants to determine if they correlate with differences in how people metabolize or respond to medications, particularly those that must cross the blood-brain barrier to be effective.
The Role of the ABCB1 Gene
The ABCB1 gene provides instructions for creating a protein known as P-glycoprotein. This protein acts as an efflux pump, which is a type of molecular machine that moves substances out of cells. P-glycoprotein is notably abundant in the blood-brain barrier, a protective network of cells that regulates what enters the brain from the bloodstream. By pumping molecules back into the blood, P-glycoprotein helps prevent certain toxins and drugs from accumulating in brain tissue. Many antidepressant medications are known substrates of this pump, meaning P-glycoprotein can recognize and transport them out of the brain. If the function of this pump is altered due to genetic variation, it is hypothesized that the concentration of medication reaching the brain could theoretically change. This mechanism is the primary reason why scientists study ABCB1 variants in the context of pharmacogenomics, aiming to understand why some individuals experience different treatment outcomes or side effects when taking the same antidepressant medication.
Evidence and Research Associations
Research into ABCB1 variants and antidepressant response has produced mixed results. While some studies suggest that specific ABCB1 polymorphisms may influence treatment efficacy or the likelihood of side effects, these findings are often inconsistent across different patient populations and medication types. For many variants in this gene, including rs12720067, the evidence remains limited. Meta-analyses and systematic reviews have highlighted that while the biological mechanism—P-glycoprotein efflux—is well-established in animal models, translating these findings into reliable clinical predictors for humans is challenging. Factors such as the specific type of antidepressant, the patient's overall genetic background, and environmental influences can all impact treatment outcomes. Consequently, the scientific community generally views the current evidence for using this specific SNP to guide clinical decision-making as insufficient. Large-scale, well-controlled clinical trials are necessary to determine if this variant has any meaningful impact on how patients respond to therapy.
Population Frequency
The rs12720067 variant is considered a common SNP, meaning it is found at a relatively high frequency across diverse human populations. Genetic databases like gnomAD and the 1000 Genomes Project provide data on how often different alleles appear in various ancestral groups. Because it is common, many individuals carry one or two copies of the variant allele. However, the frequency of the variant can vary significantly depending on geographic and ancestral background. It is important to note that being a 'common' variant does not necessarily imply a significant clinical effect; many common genetic variations have no observable impact on health or medication response. Researchers use these frequency data to ensure that studies are representative of the population and to help distinguish between rare, potentially impactful mutations and common, neutral genetic diversity.
What You Can Do With This Information
It is essential to understand that genetic information regarding variants like rs12720067 is for educational purposes and should not be used to make medical decisions. You cannot use this information to diagnose a condition, predict a specific response to a medication, or alter your current treatment plan. Pharmacogenomics is a complex field, and antidepressant response is influenced by a multitude of factors, including other genes, lifestyle, and the specific nature of the depression being treated. If you are curious about how your genetics might relate to your medication, the most appropriate step is to have a conversation with your healthcare provider or a clinical pharmacist. They can provide context based on your full medical history and current clinical guidelines. Never stop or change the dosage of a prescribed medication without direct supervision from your doctor, as doing so can have serious health consequences.
How common is this variant?
The rs12720067 variant is common across global populations, with allele frequencies varying by ancestry as documented in large-scale genomic databases.
Frequently asked questions
Can I use a genetic test to pick the best antidepressant?
While pharmacogenetic testing exists, it is not a simple 'match-making' tool for antidepressants. Current clinical guidelines suggest that genetic testing should be used as one piece of information alongside a doctor's clinical judgment, as many factors influence how well a medication works.
Is rs12720067 a reliable predictor of drug side effects?
No, the evidence for rs12720067 as a reliable predictor of side effects is limited and inconsistent. Research has not established a strong enough link to use this specific variant for clinical decision-making or predicting individual patient outcomes.
What does the ABCB1 gene do in the brain?
The ABCB1 gene produces P-glycoprotein, a protein that acts as a pump at the blood-brain barrier. It helps protect the brain by pumping out various substances, including some medications, which can affect how much of a drug stays in the brain.
Should I change my medication based on my ABCB1 genotype?
Absolutely not. You should never change your medication or dosage based on genetic test results without consulting your doctor. Genetic markers are only one part of a complex clinical picture, and stopping medication abruptly can be dangerous.
Sources & further reading
Educational information only, last refreshed 9/19/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs12720067?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ABCB1
This variant is studied for its influence on the pharmacokinetics of immunosuppressive drugs like cyclosporine and tacrolimus in transplant patients.
Synonymous variant (c.3435C>T) in ABCB1 linked to altered P-glycoprotein expression and multi-drug transporter pharmacokinetics.
Nonsynonymous variant in ABCB1 altering P-glycoprotein transporter kinetics.
This SNP is linked to variations in the pharmacokinetics of drugs that are substrates for the ABCB1 transporter protein.
A variant associated with potential differences in drug absorption and clinical outcomes in patients undergoing specific pharmacological therapies.
Synonymous polymorphism in the ABCB1 (MDR1) transporter gene influencing substrate drug efflux and systemic drug exposure.